# A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants

> **NCT07432698** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AK0406 150 mg
- **DRUG:** AK0406 300 mg
- **DRUG:** AK0406 600 mg
- **DRUG:** AK0406 900 mg
- **DRUG:** 0.9% Sodium Chloride Injection as Placebo

## Key facts

- **NCT ID:** NCT07432698
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432698, "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07432698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*